Oxolamine

• Description:

  Oxolamine (SKF-9976) is an orally active antitussive. Oxolamine can inhibit CYP2B1/2. Oxolamine has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine can be used in respiratory disease research[1][2][3][4].

• UNSPSC:

  12352005

• Target:

  Cytochrome P450

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/oxolamine.html

• Smiles:

  CCN (CC) CCC1=NC (C2=CC=CC=C2) =NO1

• Molecular Formula:

  C14H19N3O

• Molecular Weight:

  245.32

• References & Citations:

  [1]Kirilmaz L, et, al. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. Apr-Jun 1992;9 (2) :167-72.|[2]GIUDICI G, et, al. [On the anti-inflammatory action of oxolamine citrate]. Minerva Med. 1961 Oct 31;52:3752-5.|[3]Zhu X, et al. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28 (3) :125-33.|[4]Dahlgren S, et al. The effect of oxolamine citrate on experimentally produced inflammation in the respiratory organs. Acta Pharmacol Toxicol (Copenh) . 1966;24 (2) :286-96.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  CYP2

• CAS Number:

  959-14-8